The Effect of n-3 Fatty Acids on Small Dense Low-Density Lipoproteins in Patients With End-Stage Renal Disease: A Randomized Placebo-Controlled Intervention Study

Journal of Renal Nutrition

Volumn 25, Issue 4, 2015, Pages 376-380

  Sørensen, Gustav V B ^a   Svensson, My ^b   Strandhave, Charlotte ^a   Schmidt, Erik B ^a   Jørgensen, Kaj A ^b   Christensen, Jeppe H ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

AGED; BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS;

EID: 84930824169     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2015.01.021     Document Type: Article

References (33)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
2. Menon V., Gul A., Mark J.S. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005, 68:1413-1418.
3. Schwarz U., Buzello M., Ritz E., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000, 15:218-223.
4. Kwan B.C., Kronenberg F., Beddhu S., Cheung A.K. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007, 18:1246-1261.
5. Kalantar-Zadeh K., Block G., Humphreys M.H., Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
6. Deighan C.J., Caslake M.J., McConnell M., Boulton-Jones J.M., Packard C.J. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000, 35:852-862.
7. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation 1997, 95:69-75.
8. Feingold K.R., Grunfeld C., Pang M., Doerrler W., Krauss R.M. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb Vasc Biol 1992, 12:1496-1502.
9. Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis the atherosclerosis and insulin resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000, 20:2140-2147.
10. Austin M.A., Brunzell J.D., Fitch W.L., Krauss R.M. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1990, 10:520-530.
11. Austin M.A., Horowitz H., Wijsman E., Krauss R.M., Brunzell J. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis 1992, 92(1):67-77.
12. Genest J., Bard J., Fruchart J., Ordovas J.M., Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb Vasc Biol 1993, 13:1728-1737.
13. Noori N., Caulfield M.P., Salameh W.A., et al. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:2861-2870.
14. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
15. De Caterina R. N-3 fatty acids in cardiovascular disease. N Engl J Med 2011, 364:2439-2450.
16. Kelley D.S., Siegel D., Vemuri M., Mackey B.E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007, 86:324-333.
17. Suzukawa M., Abbey M., Howe P.R., Nestel P.J. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995, 36:473-484.
18. Svensson M., Schmidt E.B., Jorgensen K.A., Christensen J.H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006, 1:780-786. OPACH Study Group.
19. Rasmussen J.G., Eschen R.B., Aardestrup I.V., Dethlefsen C., Griffin B.A., Schmidt E.B. Flow-mediated vasodilatation: variation and interrelationships with plasma lipids and lipoproteins. Scand J Clin Lab Invest 2009, 69:156-160.
20. Davies I.G., Graham J.M., Griffin B.A. Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation. Clin Chem 2003, 49:1865-1872.
21. O'Neal D., Lee P., Murphy B., Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996, 27:84-91.
22. Alabakovska S.B., Todorova B.B., Labudovic D.D., Tosheska K.N. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 2002, 35:211-216.
23. Arsenault B.J., Lemieux I., Després J., et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-norfolk prospective population study. Eur Heart J 2007, 28:2770-2777.
24. Epstein M., Vaziri N.D. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012, 8:214-223.
25. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
26. Petersen M., Pedersen H., Major-Pedersen A., Jensen T., Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002, 25:1704-1708.
27. Mostad I., Bjerve K., Lydersen S., Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 2007, 62:419-429.
28. Harris W.S. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65(Suppl 5):1645S-1654S.
29. Pei J., Zhao Y., Huang L., Zhang X., Wu Y. The effect of n-3 polyunsaturated fatty acids on plasma lipids and lipoproteins in patients with chronic renal failure-a meta-analysis of randomized controlled trials. J Ren Nutr 2012, 22:525-532.
30. Ikejiri A., Hirano T., Murayama S., et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004, 53:1113-1117.
31. Dornbrook-Lavender K.A., Joy M.S., Denu-Ciocca C.J., Chin H., Hogan S.L., Pieper J.A. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005, 25:335-344.
32. Van den Akker J., Bredie S., Diepenveen S., Van Tits L., Stalenhoef A., Van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and invivo oxidized LDL. J Nephrol 2002, 16:238-244.
33. Damico K.E., Stoll A.L., Marangell L.B., Cohen B.M. How blind is double-blind? A study of fish oil versus placebo. Prostaglandins Leukot Essent Fatty Acids 2002, 66:393-395.